RegeneRx Biopharmaceuticals Inc (NASDAQ:RGRX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday. They presently have a $2.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 440.54% from the stock’s previous close.
Shares of RegeneRx Biopharmaceuticals (NASDAQ:RGRX) opened at 0.37 on Thursday. The company has a 50-day moving average of $0.38 and a 200-day moving average of $0.48. The firm’s market cap is $39.51 million. RegeneRx Biopharmaceuticals has a 1-year low of $0.28 and a 1-year high of $0.75.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
Receive News & Ratings for RegeneRx Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.